肾小球肾炎临床试验的新方法
本文讨论肾小球肾炎(GN)随机对照试验的现状与改进方向。目前约790项GN试验因设计报告欠佳和样本量小可能不可靠,但患者参与、试验网络、核心结局集、注册库试验和适应性设计等新举措有望提升证据质量。
要点
- 随机对照试验是可靠评估GN干预措施的必要手段。
- 现有约790项GN试验因设计和样本量问题可能不可靠。
- 患者参与、试验网络和适应性设计等新方法可改善证据质量。
核心结论
- 需要破坏性技术和文化变革来实现试验改善GN患者健康的潜力。
研究设计与样本
- 本文为综述,讨论GN临床试验的现状与改进策略。
主要发现
- 目前约有790项GN试验,但设计报告欠佳和样本量小可能影响决策可靠性。
- 观察性研究虽然更简单,但本质上不可靠,即使与随机对照试验结果多数一致。
临床怎么用
- 临床决策应关注试验质量和样本量,而非仅依赖观察性研究。
- 可参与患者参与、试验网络和注册库试验等新举措以提高证据质量。
局限性
- 原文未系统报告综述的检索范围和方法学局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Randomized controlled trials are required to reliably identify interventions to improve the outcomes for people with glomerulonephritis (GN). Unfortunately, although easier, observational studies are inherently unreliable even though the findings of both study designs agree most of the time. Currently there are ∼790 trials in GN, but suboptimal design and reporting, together with small sample sizes, mean that they may not be reliable for decision making. If the history is somewhat bleak, the future looks bright, with recent initiatives to improve the quality, size and relevance of clinical trials in nephrology, including greater patient engagement, trial networks, core outcome sets, registry-based trials and adaptive designs. Given the current state of the evidence informing the care of people with GN, disruptive technologies and pervasive culture change is required to ensure that the potential of trials to improve the health of people with this complex condition is to be realized.
引用
- Craig JC, Tong A, Strippoli GF, et al. New approaches to trials in glomerulonephritis. Nephrol Dial Transplant. 2017. PMID: 28391345. doi:10.1093/ndt/gfw364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。